These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 14634048)

  • 1. Antithrombotic effects of FK419, a novel nonpeptide platelet GPIIb/IIIa antagonist, in a guinea pig photochemically induced middle cerebral artery thrombosis model: comparison with ozagrel and argatroban.
    Moriguchi A; Aoki T; Mihara K; Tojo N; Matsuoka N; Mutoh S
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1094-101. PubMed ID: 14634048
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of middle cerebral artery thrombosis by novel glycoprotein IIb/IIIa antagonist FK419 in guinea pig.
    Moriguchi A; Mihara K; Aoki T; Maeda M; Tojo N; Matsuoka N; Mutoh S
    Eur J Pharmacol; 2004 Sep; 498(1-3):179-88. PubMed ID: 15363993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FK419, a novel nonpeptide GPIIb/IIIa antagonist, restores microvascular patency and improves outcome in the guinea-pig middle cerebral artery thrombotic occlusion model: comparison with tirofiban.
    Moriguchi A; Maeda M; Mihara K; Aoki T; Matsuoka N; Mutoh S
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):75-86. PubMed ID: 15678114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator.
    Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T
    J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thromboxane A(2) synthase inhibitor enhanced antithrombotic efficacy of GPIIb-IIIa receptor antagonist without increasing bleeding.
    Kawano KI; Hokamura K; Kondo K; Ikeda Y; Suzuki Y; Umemura K
    Eur J Pharmacol; 2001 Apr; 417(3):217-22. PubMed ID: 11334853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of platelet integrin GPIIb-IIIa receptor antagonist over aspirin in preventing cyclic flow reductions in the guinea pig middle cerebral artery.
    Kawano K; Ikeda Y; Kondo K; Umemura K
    Eur J Pharmacol; 1999 Jun; 374(3):377-85. PubMed ID: 10422782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ME3277, a GPIIb/IIIa antagonist reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery.
    Kawano KI; Fujishima K; Ikeda Y; Kondo K; Umemura K
    J Cereb Blood Flow Metab; 2000 Jun; 20(6):988-97. PubMed ID: 10894182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antagonism of the GPIIb/IIIa receptor with the nonpeptidic molecule BIBU52: inhibition of platelet aggregation in vitro and antithrombotic efficacy in vivo.
    Guth BD; Seewaldt-Becker E; Himmelsbach F; Weisenberger H; Müller TH
    J Cardiovasc Pharmacol; 1997 Aug; 30(2):261-72. PubMed ID: 9269956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrin alpha(IIb)beta(3) inhibitor preserves microvascular patency in experimental acute focal cerebral ischemia.
    Abumiya T; Fitridge R; Mazur C; Copeland BR; Koziol JA; Tschopp JF; Pierschbacher MD; del Zoppo GJ
    Stroke; 2000 Jun; 31(6):1402-09; discussion 1409-10. PubMed ID: 10835463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, and structure-activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419.
    Yamanaka T; Ohkubo M; Kuroda S; Nakamura H; Takahashi F; Aoki T; Mihara K; Seki J; Kato M
    Bioorg Med Chem; 2005 Jul; 13(13):4343-52. PubMed ID: 15927840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.
    Choudhri TF; Hoh BL; Zerwes HG; Prestigiacomo CJ; Kim SC; Connolly ES; Kottirsch G; Pinsky DJ
    J Clin Invest; 1998 Oct; 102(7):1301-10. PubMed ID: 9769322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a GPIIb/IIIa antagonist YM337 in a primate model of middle cerebral artery thrombosis.
    Kaku S; Umemura K; Mizuno A; Yano S; Suzuki K; Kawasaki T; Nakashima M
    Eur J Pharmacol; 1998 Mar; 345(2):185-92. PubMed ID: 9600636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antithrombotic effects of TAK-029, a novel GPIIb/IIIa antagonist, in guinea pigs: comparative studies with ticlopidine, clopidogrel, aspirin, prostaglandin E1 and argatroban.
    Kawamura M; Imura Y; Moriya N; Kita S; Fukushi H; Sugihara H; Nishikawa K; Terashita Z
    J Pharmacol Exp Ther; 1996 Apr; 277(1):502-10. PubMed ID: 8613960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of platelet glycoprotein IIb/IIIa receptor antagonists in the management of ischemic stroke.
    Lapchak PA; Araujo DM
    Am J Cardiovasc Drugs; 2003; 3(2):87-94. PubMed ID: 14727935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of antithrombotic effects of GPIIb-IIIa receptor antagonist and TXA2 receptor antagonist in the guinea-pig thrombosis model: possible role of TXA2 in reocclusion after thrombolysis.
    Takiguchi Y; Asai F; Wada K; Nakashima M
    Thromb Haemost; 1995 Apr; 73(4):683-8. PubMed ID: 7495079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous and oral antiplatelet/antithrombotic efficacy and specificity of XR300, a novel nonpeptide platelet GPIIb/IIIa antagonist.
    Mousa SA; Forsythe M; Wityak J; Bozarth J; Mu DX
    J Cardiovasc Pharmacol; 1998 Mar; 31(3):441-8. PubMed ID: 9514190
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antithrombotic effect of SM-20302, a nonpeptide GPIIb/IIIa antagonist, in a photochemically induced thrombosis model in guinea pigs.
    Horisawa S; Kaneko M; Ikeda Y; Ueki Y; Sakurama T
    Thromb Res; 1999 May; 94(4):227-34. PubMed ID: 10336238
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet and antithrombotic effects of YM337, the Fab fragment of a humanized anti-GPIIb/IIIa monoclonal antibody in monkeys.
    Kaku S; Kawasaki T; Hisamichi N; Sakai Y; Taniuchi Y; Inagaki O; Yano S; Suzuki K; Terazaki C; Masuho Y; Satoh N; Takenaka T; Yanagi K; Ohshima N
    Thromb Haemost; 1996 Apr; 75(4):679-84. PubMed ID: 8743199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet and antithrombotic activity of RWJ-53308, a novel orally active glycoprotein IIb/IIIa antagonist.
    Damiano BP; Mitchell JA; Giardino E; Corcoran T; Haertlein BJ; de Garavilla L; Kauffman JA; Hoekstra WJ; Maryanoff BE; Andrade-Gordon P
    Thromb Res; 2001 Oct; 104(2):113-26. PubMed ID: 11672755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.